Belite Bio, Inc (BLTE)

42.05 -0.45 (-1.06%) At close: 04:00PM EDT

Belite Bio, Inc

12750 High Bluff Drive
Suite 475
San Diego, CA 92130
United States
858 246 6240
https://www.belitebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 20

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yu-Hsin Lin M.B.A., Ph.D.	Chairman of the Board of Directors & CEO	N/A	N/A	1979
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A.	CFO & Director	N/A	N/A	1985
Dr. Nathan L. Mata Ph.D.	Chief Scientific Officer	N/A	N/A	1967

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Corporate governance

Belite Bio, Inc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.